首页> 外文OA文献 >The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

【2h】

The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

机译：血清CEA和CA19-9在用西司昔单抗与Folfox4或Folfiri合并作为晚期结直肠癌的一线治疗的患者的疗效评估中的作用和无进展生存预测

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jun Jia; Pengfei Zhang; Miaomiao Gou; Fan Yang; Niansong Qian; Guanghai Dai;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer [J] . Jun Jia, Pengfei Zhang, Miaomiao Gou, Disease markers . 2019,第Pta1期

机译：血清CEA和Ca19-9在用西司昔单抗与Folfox4或Folfiri联合的患者的疗效评估和无进展生存预测的作用作为晚期结直肠癌的一线治疗
2. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer [J] . Jun Jia, Pengfei Zhang, Miaomiao Gou, Disease markers . 2019,第2a3期

机译：血清CEA和CA19-9在用西司昔单抗与Folfox4或Folfiri合并作为晚期结直肠癌的一线治疗的患者的疗效评估中的作用和无进展生存预测
3. 3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer [J] . T.E.Ciuleanu, W.Scheithauer, G.Kurteva, European Journal of Cancer Supplements . 2007,第4期

机译：3046 POSTER：一项评估FOLFOX6 +西妥昔单抗与FOLFIRI +西妥昔单抗作为转移性结直肠癌患者一线治疗的疗效和安全性的随机，开放标签II期研究
4. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer [O] . Jun Jia, Pengfei Zhang, Miaomiao Gou, 2019

机译：血清CEA和CA19-9在西妥昔单抗联合FOLFOX4或FOLFIRI作为晚期大肠癌一线治疗的患者的疗效评估和无进展生存期预测中的作用
5. The dynamics of the serum concentration of CEA, CA15-3 and CA19-9 and survival in patients treated for advanced breast and colorectal cancer. The determination of the prognostic correlates of changes in tumour markers CEA, CA15-3 and CA19-9 during chemotherapy treatment for advanced breast and colorectal cancer. [O] . Barker Laura Caroline 2010

机译：晚期乳腺癌和结直肠癌患者血清CEA，CA15-3和CA19-9的浓度动态及生存率。确定晚期乳腺癌和大肠癌化疗期间肿瘤标志物CEA，CA15-3和CA19-9变化的预后相关性。

The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅